Fri, August 9, 2024

Asthika Goonewardene Reiterated (ALLO) at Strong Buy with Decreased Target to $14 on, Aug 9th, 2024

Asthika Goonewardene of Truist Securities, Reiterated "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Decreased Target from $17 to $14 on, Aug 9th, 2024.

Asthika has made no other calls on ALLO in the last 4 months.



There are 6 other peers that have a rating on ALLO. Out of the 6 peers that are also analyzing ALLO, 1 agrees with Asthika's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Benjamin Burnett of "Stifel" Maintained at Hold with Increased Target to $4.6 on, Tuesday, May 14th, 2024


These are the ratings of the 5 analyists that currently disagree with Asthika


  • John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $14 on, Thursday, August 8th, 2024
  • Matthew Biegler of "Oppenheimer" Initiated at Buy with Decreased Target to $11 on, Thursday, August 8th, 2024
  • Biren Amin of "Piper Sandler" Initiated at Buy and Held Target at $11 on, Friday, May 31st, 2024
  • Mark Breidenbach of "Oppenheimer" Maintained at Buy with Decreased Target to $13 on, Tuesday, May 21st, 2024
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $9 on, Thursday, May 16th, 2024